STOCK TITAN
  1. Home
  2. Sec-filings
  3. glue
  4. [Form 4] Monte Rosa Therapeutics, Inc. Insider Trading Activity

Director at Monte Rosa (GLUE) awarded 25,800 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Monte Rosa Therapeutics director Ali Behbahani received a grant of stock options for 25,800 shares of common stock. The options have an exercise price of $17.10 per share and expire on June 11, 2036. They vest in full on the earlier of June 11, 2027 or the company’s next annual stockholder meeting, subject to his continued service.

Positive

  • None.

Negative

  • None.
Insider Behbahani Ali
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 25,800 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 25,800 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Stock options granted 25,800 options Grant of stock options to director Ali Behbahani
Exercise price $17.10 per share Exercise price for the 25,800 stock options
Expiration date June 11, 2036 Options expiration for Behbahani grant
Total derivative holdings after grant 25,800 options Total derivative securities following this transaction
Underlying shares 25,800 shares Common stock underlying the granted options
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 17.1000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The shares subject to this option shall vest and become exercisable in full"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
annual meeting of stockholders financial
"the Issuer's next annual meeting of stockholders"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Behbahani Ali
(Last)(First)(Middle)
2855 SAND HILL ROAD
(Street)
MENLO PARK CALIFORNIA 94025
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Monte Rosa Therapeutics, Inc. [ GLUE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$17.106/11/2026A25,800 (1)06/11/2036Common Stock25,800$025,800D
Explanation of Responses:
1. The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time.
/s/ Zachary Bambach, attorney-in-fact06/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Monte Rosa Therapeutics (GLUE) director Ali Behbahani report on this Form 4?

Ali Behbahani reported receiving a grant of stock options for 25,800 shares of Monte Rosa Therapeutics common stock. The filing classifies this as a grant or award acquisition, reflecting equity-based compensation rather than an open-market stock purchase or sale.

What are the key terms of the 25,800 Monte Rosa (GLUE) stock options granted?

The granted stock options cover 25,800 shares with an exercise price of $17.10 per share and an expiration date of June 11, 2036. These terms define how many shares can be purchased, at what price, and how long the options remain exercisable.

When do Ali Behbahani’s Monte Rosa (GLUE) stock options vest?

The options vest and become exercisable in full on the earlier of June 11, 2027 or Monte Rosa’s next annual meeting of stockholders. Vesting is conditioned on Behbahani’s continued service with the company through that vesting date, according to the filing footnote.

Is this Monte Rosa (GLUE) Form 4 an open-market stock purchase or sale?

No, this Form 4 reports a grant of stock options, not an open-market trade. The transaction code is A, described as a grant, award, or other acquisition, indicating equity compensation rather than buying or selling existing shares in the market.

How many Monte Rosa (GLUE) derivative securities does Ali Behbahani hold after this grant?

After this transaction, Behbahani holds 25,800 derivative securities related to Monte Rosa common stock, according to the Form 4. These represent the stock options granted in this filing and correspond to 25,800 underlying shares if fully exercised in the future.